The Parkinson’s Institute and Clinical Center and Denali Therapeutics Inc.s announced a partnership to explore new clinical endpoints for studies in patients with Parkinson’s Disease (PD).
The Institute and Denali aim to support the development of new PD therapeutics by better understanding the potential of new endpoints for clinical studies. Known clinical endpoints for PD can be affected by current standard treatments which, in turn, may confound the measurement of new therapeutics’ impact.
The agreement brings together the unique expertise of the Institute and its broad patient experience with Denali as it continues the development of its LRRK2 inhibitor clinical program for Parkinson’s Disease.
“This collaboration will allow us to explore new clinical endpoints that may help determine whether therapeutics like Denali’s LRRK2 inhibitors have a measurable effect on Parkinson’s patients,” said Chief Executive Officer, Parkinson’s Institute and Clinical Center, Carrolee Barlow, M.D., Ph.D.
“We are very enthusiastic about partnering with the Parkinson’s Institute, which has done so much to support and foster the development of new approaches to drug development. Having demonstrated our lead LRRK2 inhibitor in the clinic can reduce LRRK2 kinase activity, we are looking forward to exploring the potential of new endpoints for clinical studies in patients,” said Denali Chief Medical Officer and Head of Development, Carole Ho, M.D.
Today’s announcement opens the door to potential future collaborations based on the outcome of the exploration into new endpoints.
